Evaxion Biotech A/S (EVAX)
Market Closed
12 Mar, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
1. 87
-0.04
-2.09%
Pre Market
$
0 0% 1. 87
9.68M Market Cap
- P/E Ratio
0% Div Yield
113,119 Volume
-2.08 Eps
$ 1.91
Previous Close Day Range
1.84 1.98
Year Range
1.7 22.05
Earnings results expected in 11 days
Summary
EVAX closed yesterday lower at $1.87, a decrease of 2.09% from Tuesday's close, completing a monthly decrease of -56.51% or $2.43. Over the past 12 months, EVAX stock lost -76.62%.
EVAX is not paying dividends to its shareholders.
The last earnings report, released on Dec 17, 2024, exceeded the consensus estimates by 0.31%. On average, the company has surpassed earnings expectations by 0.32%, based on the last three reports. The next scheduled earnings report is due on Mar 25, 2025.
Evaxion Biotech A/S has completed 3 stock splits, with the recent split occurring on Jan 14, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track EVAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
EVAX Chart
Evaxion Biotech A/S Dividends
EVAX is not paying dividends to its shareholders.
Evaxion Biotech A/S Earnings
| 26 May 2025 (73 Days) Date | | - Cons. EPS | - EPS |
| 25 Mar 2025 (11 Days) Date | | - Cons. EPS | - EPS |
| 17 Dec 2024 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 16 Aug 2024 Date | | - Cons. EPS | - EPS |
EVAX is not paying dividends to its shareholders.
| 26 May 2025 (73 Days) Date | | - Cons. EPS | - EPS |
| 25 Mar 2025 (11 Days) Date | | - Cons. EPS | - EPS |
| 17 Dec 2024 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 16 Aug 2024 Date | | - Cons. EPS | - EPS |
Evaxion Biotech A/S (EVAX) FAQ
What is the stock price today?
The current price is $1.87.
On which exchange is it traded?
Evaxion Biotech A/S is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is EVAX.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 9.68M.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Mar 25, 2025.
Has Evaxion Biotech A/S ever had a stock split?
Evaxion Biotech A/S had 3 splits and the recent split was on Jan 14, 2025.
Evaxion Biotech A/S Profile
| Biotechnology Industry | Healthcare Sector | Mr. Christian Kanstrup M.Sc. CEO | NASDAQ (CM) Exchange | US29970R1059 ISIN |
| US Country | 49 Employees | - Last Dividend | 22 Jan 2024 Last Split | 5 Feb 2021 IPO Date |
Overview
Evaxion Biotech A/S represents a forefront clinical-stage biotech entity distinguished by its specialized focus on the development of immunotherapies powered by artificial intelligence. Incorporated in 2008 and having its foundations in Horsholm, Denmark, the company is pioneering in the research and development of novel treatments targeting a range of cancers and infectious diseases. By leveraging the potential of AI, Evaxion Biotech A/S aims to enhance the precision and effectiveness of immunotherapies, paving the way for significant advancements in medical treatments.
Products and Services
Evaxion Biotech A/S boasts an extensive portfolio concentrated on immunotherapies and vaccines, each at varying stages of clinical and pre-clinical development. The following outlines their primary products and services:
- EVX-01: A cutting-edge cancer immunotherapy that is currently undergoing a clinical Phase IIb trial focusing on metastatic melanoma. EVX-01 utilizes the body's immune system to target and destroy cancer cells, representing a potential leap forward in melanoma treatment.
- EVX-02: This is a DNA-based cancer immunotherapy in a Phase 1/2a trial for adjuvant melanoma. By encoding antigens that are specifically expressed on melanoma cells, EVX-02 aims to stimulate an immune response targeted at eradicating these cancer cells.
- EVX-03: As a DNA-based immunotherapy, EVX-03 targets the treatment of various cancers through a patient-specific approach. This strategy holds the promise of tailoring treatments to an individual’s cancer profile, offering a highly personalized therapy option.
- EVX-B1: In the pre-clinical stage, EVX-B1 is a vaccine candidate designed to combat bacterial diseases. Leveraging the body's immune response to bacterial pathogens, this vaccine aims to provide a robust protective shield against multiple bacterial infections.
- EVX-B2: Similar to EVX-B1, this vaccine is also in the pre-clinical phase and is aimed at treating other bacterial diseases not covered by EVX-B1. Through meticulous research and development, EVX-B2 seeks to expand the spectrum of bacterial infections that can be effectively prevented.
- EVX-V1: This pre-clinical stage vaccine targets viral diseases, harnessing the power of the immune system to prevent infections from a range of viruses. With the ongoing threat of viral pandemics, EVX-V1 represents a vital component of Evaxion Biotech A/S’s endeavor to combat viral diseases globally.
Contact Information
Address: Dr. Neergaards Vej, Horsholm, Denmark, 2970
Phone: 45 53 53 18 50
Website: https://www.evaxion-biotech.com
2025 © Marketlog. All Rights Reserved.
